NCT07443592 2026-03-02
LAL-2025
PETHEMA Foundation
Phase NA Not yet recruiting
Clinical Trials
10 trialsNCT07131059 2025-08-20
MRD-positive AML Clinical Study
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Recruiting
NCT07003737 2025-06-04
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University
Phase NA Recruiting
NCT06885476 2025-03-20
Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase NA Recruiting
NCT06301425 2024-07-10
MRD Response-adapted Allo-HSCT for Adverse-risk AML
Peking University People's Hospital
Phase NA Recruiting
NCT06090786 2024-04-10
Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Not yet recruiting
NCT06066905 2023-10-27
A Study of Chidamide With AZA in MRD Positive AML After Transplant
Guangdong Provincial People's Hospital
Phase NA Recruiting
NCT05093192 2023-09-08
Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia
University of Bath
Phase NA Completed
NCT04179929 2022-02-18
Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults
PETHEMA Foundation
Phase NA Recruiting
NCT02185261 2018-06-07
Interferon α for the Therapy of Minimal Residual Disease
Peking University People's Hospital
Phase NA Unknown